Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.
about
Inhaled corticosteroids with combination inhaled long-acting beta 2 -agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary diseaseCombined aclidinium bromide and long-acting beta 2 -agonist for COPDSafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studySpecific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary diseaseCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseInhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment ParadigmTreatment evolution after COPD diagnosis in the UK primary care setting.The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.COPD: maximization of bronchodilation.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.Is 'GOLD' standard for the management of COPD in clinical practice?An update on bronchodilators in Phase I and II clinical trials.Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.Recent advances in COPD disease management with fixed-dose long-acting combination therapies.Umeclidinium for the treatment of chronic obstructive pulmonary disease.QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to dateBronchodilators, receptors and cross-talk: Together is better?Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.Bifunctional Drugs for the Treatment of Respiratory Diseases.Safety of inhaled long-acting anti-muscarinic agents in COPD.Oropharyngeal and Sputum Microbiomes Are Similar Following Exacerbation of Chronic Obstructive Pulmonary DiseaseAclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.Olodaterol + tiotropium bromide for the treatment of COPD.Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease
P2860
Q24186966-6C9199CD-CBA0-4943-8ED6-084D27BD20BEQ24187613-F6A7CD7F-0FE7-4AB4-86E9-91C6E8140C5EQ24561751-D52A79BD-1751-403C-9030-F822162937CEQ26770504-133032F9-FD2D-402D-BE8F-D5E2D729B65BQ27012625-B4D1DD82-40C7-4B0F-9F5C-D8A87D827EA3Q28087788-93EBB67B-3A4C-4970-B785-0F1BE5006EB9Q34121263-39ED93C2-8AFE-40A9-A5A3-CD1AFC9C15CFQ34368537-AA2E9D42-C3FC-4835-8DB0-95093EA34F67Q34436393-A4A4402B-8079-4814-B8CE-13F7C8DD6D62Q34550471-E6474292-D717-47D5-A8A6-560FEF2E0F6CQ35350962-1C2A65AB-BA1F-4C29-9B92-E7E7D4EF2BFDQ35766346-7DFB0A4D-7A19-4DCF-9667-C70714BFBD58Q36188224-489CB0A9-D53B-427F-BE5D-A4CB3A7216CCQ37001907-9BB13B1F-79CC-4759-85E7-3D1722D01AE7Q37170227-212C7F18-E69F-4DF8-9E91-4240EE9545FBQ37209304-5AAC0951-1C77-4A6D-B2EB-DF0C0744FD4DQ37450159-EFC3C215-B88B-4DC7-A985-E9CFFEF13516Q38037123-26BE8650-5E89-4EC7-B682-62B94241A1B0Q38057220-04F9CE8E-8DA6-4A36-A344-C88586EF921EQ38095562-7B1C46B1-D945-439B-B96C-EC3C5D28CD8DQ38154255-35590E46-D28F-4958-ADE8-2F6FE5B1FD18Q38199533-FD0322A8-4E69-41B9-A644-B1A636F9CD59Q38209841-ADA96734-E5D0-4EB8-8663-BC5E203DB14DQ38259862-D22CA158-B371-46C2-BF79-CEAAC699AF3DQ38406157-65672E32-00B8-4BE6-82DD-BC41704E585DQ38432438-01E17A3D-0000-400F-BAE5-5B7F38BC51B0Q38570698-7CE405F9-064B-4D72-AC26-0BE5DF100F3DQ38570714-C8C37857-F107-40CF-9A66-6C021A5B40D6Q38740756-76D05DE5-6B33-4853-ACCF-713F14BB014BQ38754002-5B17076B-643D-47BB-AC98-9F061FA7B298Q38982942-B933281A-428D-4025-85DB-694C76C3FE8AQ38992596-E851D514-F8B1-4929-B392-B466853A3EE5Q39232425-FBBFBAC5-80A6-4053-B7DD-D93F6552DB5FQ41073125-E395EA27-1400-4377-8D4C-3A38B98AA032Q43695468-FA80E490-BE1F-4CD4-926E-C73EB5E4B092Q47984024-7FAC5C89-059D-40E8-B37E-08B2F6DFB2DFQ51545895-8BBB2A8C-53E2-4C31-8FB4-301BCCFF095EQ55451529-6ACE8BF6-42CF-41B8-8786-924A908B28BDQ58765841-EB16597E-5206-4E7F-A33E-C46594C8C9F4
P2860
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Beyond lung function in COPD m ...... y on patient-centred outcomes.
@en
Beyond lung function in COPD m ...... y on patient-centred outcomes.
@nl
type
label
Beyond lung function in COPD m ...... y on patient-centred outcomes.
@en
Beyond lung function in COPD m ...... y on patient-centred outcomes.
@nl
prefLabel
Beyond lung function in COPD m ...... y on patient-centred outcomes.
@en
Beyond lung function in COPD m ...... y on patient-centred outcomes.
@nl
P2860
P356
P1476
Beyond lung function in COPD m ...... py on patient-centred outcomes
@en
P2093
Mario Cazzola
Thys van der Molen
P2860
P2888
P304
P356
10.4104/PCRJ.2011.00102
P577
2012-03-01T00:00:00Z
P5875
P6179
1012615502